Trial Profile
Safety Surveillance Scheme (IS3) in miglustat (Zavesca) treated patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2017
Price :
$35
*
At a glance
- Drugs Miglustat (Primary)
- Indications Gaucher's disease type I
- Focus Adverse reactions
- Acronyms IS3
- 11 Dec 2017 New trial record